Development and characterization of neutralizing monoclonal antibodies against clinically relevant human adenovirus subgroup B serotypes

: 30.4 μg/mL). Western blot analysis revealed that MAbs 13F12 and 8F2 targeted the fiber protein, whereas 8D2 and 3A3 bound to the hexon protein. Furthermore, in vivo evaluations demonstrated that 13F12 significantly reduced viral loads in nasal turbinates and attenuated lung pathology in HAdV-3-infected tree shrews. Mechanistically, all tested anti-HAdV-3 nMAbs inhibited infection by blocking viral attachment (P < 0.01 vs. controls). In conclusion, this study underscores the therapeutic potential of targeting viral entry and highlights 13F12 as a promising candidate for HAdV prophylaxis.

Authors

Institutions

Publication Details

Journal
Virologica Sinica
Published
2026-04-01
DOI
https://doi.org/10.1016/j.virs.2026.03.017
Primary Topic
Virus-based gene therapy research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Development and characterization of neutralizing monoclonal antibodies against clinically relevant human adenovirus subgroup B serotypes

Vladislav Victorovich Khrustalev, Wei Dou, Yushan Jiang, Alexey Viktorovich Churov et al.
Virologica Sinica
Virus-based gene therapy research
article

Development and characterization of neutralizing monoclonal antibodies against clinically relevant human adenovirus subgroup B serotypes

Vladislav Victorovich Khrustalev, Wei Dou, Yushan Jiang, Alexey Viktorovich Churov, Yingying Chen, Yuelin Wang, Ling Li, Chenguang Shen, Alexander N. Orekhov, Mengjun Li, Tyuji Hoshino, Ke Liu
article en

Abstract

: 30.4 μg/mL). Western blot analysis revealed that MAbs 13F12 and 8F2 targeted the fiber protein, whereas 8D2 and 3A3 bound to the hexon protein. Furthermore, in vivo evaluations demonstrated that 13F12 significantly reduced viral loads in nasal turbinates and attenuated lung pathology in HAdV-3-infected tree shrews. Mechanistically, all tested anti-HAdV-3 nMAbs inhibited infection by blocking viral attachment (P < 0.01 vs. controls). In conclusion, this study underscores the therapeutic potential of targeting viral entry and highlights 13F12 as a promising candidate for HAdV prophylaxis.

Virologica Sinica
Chiba University (JP), Southern University of Science and Technology (CN), Third Affiliated Hospital of Southern Medical University (CN), Research Institute of General Pathology and Pathophysiology, the Russian Academy of Medical Sciences (RU), Belarusian State Medical University (BY), Southern Medical University (CN)
National Natural Science Foundation of China, Guangdong Provincial Applied Science and Technology Research and Development Program, Guangzhou Science and Technology Program key projects, Science and Technology Planning Project of Guangdong Province, Basic and Applied Basic Research Foundation of Guangdong Province
Good health and well-being
Openalex Percentile: Top 35%
Virus-based gene therapy research
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.